The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

24 Health Systems Are Dropping Medicare Advantage Plans in 2026

At least 24 health systems are severing ties with specific Medicare Advantage plans for 2026, continuing a trend Becker's Hospital Review has tracked since 2023. The common complaints are familiar: heavy prior authorization burdens, frequent care denials, and reimbursement that arrives slowly or falls short of traditional Medicare rates.

The stakes are rising because Medicare Advantage now covers more than half of the nation's older adults. When a system drops a plan, patients enrolled in that product can lose in-network access to their usual hospitals and physicians, forcing them to switch providers, switch plans, or pay out of network. That makes each termination more consequential than it would have been a few years ago.

The pattern reflects a broader standoff between providers and insurers over the economics of MA. Hospitals argue the administrative friction and payment delays no longer justify the volume. For payers and patients, the contraction signals that the once near-universal acceptance of MA plans can no longer be assumed heading into open enrollment.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.